The Indian pharmaceutical industry has faced significant challenges in recent years, but 2022 has been a defining year for the sector. The industry has had to navigate disruptions caused by the COVID-19 pandemic, regulatory changes, and global trade tensions. Despite these challenges, Indian pharma has shown resilience and adaptability, and is now preparing for a new global order.<\/p>\n
One of the major disruptions faced by the industry has been the pandemic, which has led to supply chain disruptions, lockdowns, and changes in demand patterns. However, Indian pharma companies have responded by investing in digital transformation, diversifying their product portfolios, and expanding their global footprint. The industry has also seen a significant increase in investments in research and development, with a focus on developing new and innovative products.<\/p>\n
Regulatory changes have also been a major challenge for the industry. The Indian government has introduced several policies aimed at promoting the domestic pharmaceutical industry, including the Production Linked Incentive (PLI) scheme, which provides incentives to companies that invest in domestic manufacturing. The government has also introduced new regulations aimed at improving the quality of pharmaceutical products and reducing the risk of counterfeit medicines.<\/p>\n
Despite these challenges, the Indian pharmaceutical industry has continued to grow, with exports increasing by over 20% in the past year. The industry has also seen a significant increase in foreign investments, with several global companies investing in Indian pharma companies. The industry is also expected to benefit from the government’s efforts to promote the development of a domestic pharmaceutical industry, including the establishment of pharmaceutical parks and clusters.<\/p>\n
As the industry prepares for a new global order, it is likely to face new challenges and opportunities. The COVID-19 pandemic has accelerated the trend towards digitalization and online healthcare, and Indian pharma companies will need to invest in digital technologies to remain competitive. The industry will also need to navigate the changing global trade landscape, including the impact of Brexit and the US-China trade war.<\/p>\n
Overall, 2022 has been a defining year for the Indian pharmaceutical industry, with the sector navigating significant disruptions and preparing for a new global order. The industry has shown resilience and adaptability, and is well-positioned to take advantage of new opportunities and challenges in the coming years. With the government’s support and the industry’s own efforts, Indian pharma is likely to continue to grow and thrive, and play an increasingly important role in the global pharmaceutical industry. <\/p>\n
Indian pharma companies are working to develop new and innovative products, including vaccines, biologics, and gene therapies. The industry is also investing in emerging technologies such as artificial intelligence, blockchain, and the Internet of Things (IoT) to improve the quality and efficiency of its operations. As the industry looks to the future, it is clear that Indian pharma will play an increasingly important role in the global pharmaceutical industry, and will continue to be a major driver of economic growth and innovation in India.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Indian pharmaceutical industry has faced significant challenges in recent years, but 2022 has been a defining year for the sector. The industry has had to navigate disruptions caused by the COVID-19 pandemic, regulatory changes, and global trade tensions. Despite these challenges, Indian pharma has shown resilience and adaptability, and is now preparing for a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-89744","post","type-post","status-publish","format-standard","hentry","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89809,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/indian-pharma-q3-preview-strong-domestic-formulations-segment-to-offset-us-pricing-challenges-scanx-trade\/","url_meta":{"origin":89744,"position":0},"title":"Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector's growth is anticipated to be driven by a strong performance in the domestic market, which is\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89766,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/08\/anand-rathis-siddharth-sedani-reveals-his-top-4-stock-picks-do-they-feature-in-your-investment-portfolio\/","url_meta":{"origin":89744,"position":1},"title":"Anand Rathi’s Siddharth Sedani reveals his top 4 stock picks – do they feature in your investment portfolio?","author":"Team Small News","date":"January 8, 2026","format":false,"excerpt":"The Indian pharmaceutical sector is offering investors a chance to build a strong portfolio under the theme \"Ayush Kart\", as stated by Siddharth Sedani, Managing Director at Anand Rathi. The Indian pharma sector has been growing rapidly, and this trend is expected to continue, making it an attractive investment opportunity.\u2026","rel":"","context":"In "Divi's Laboratories"","block_context":{"text":"Divi's Laboratories","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/divis-laboratories\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89806,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/us-sales-of-revlimid-decline-offset-by-strong-domestic-market-growth\/","url_meta":{"origin":89744,"position":2},"title":"US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89777,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/10\/jefferies-names-sai-life-and-divis-labs-as-top-choices-in-the-contract-research-and-development-manufacturing-organization-crdmo-sector-while-reducing-target-prices-for-piramal-pharma-and-cohance\/","url_meta":{"origin":89744,"position":3},"title":"Jefferies names Sai Life and Divi’s Labs as top choices in the contract research and development manufacturing organization (CRDMO) sector, while reducing target prices for Piramal Pharma and Cohance.","author":"Team Small News","date":"January 10, 2026","format":false,"excerpt":"Jefferies, a global investment bank, has released its latest report on the Contract Research and Development Manufacturing Organization (CRDMO) sector. The report highlights top picks and revises target prices for several key players in the industry. Sai Life Sciences and Divi's Labs have emerged as Jefferies' top picks in the\u2026","rel":"","context":"In "Divi's Laboratories"","block_context":{"text":"Divi's Laboratories","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/divis-laboratories\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89821,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/sun-pharma-sets-sights-on-10-billion-organon-takeover-to-bolster-us-presence\/","url_meta":{"origin":89744,"position":4},"title":"Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., India's largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women's health and biosimilars. The potential deal, valued at $10 billion, is being led by the company's founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89791,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/aurobindo-pharma-acquires-khandelwal-labs-non-cancer-portfolio-for-%e2%82%b9325-crore\/","url_meta":{"origin":89744,"position":5},"title":"Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for \u20b9325 Crore.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89744"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89744\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}